Biointerfacing Antagonizing T‐Cell Inhibitory Nanoparticles Potentiate Hepatocellular Carcinoma Checkpoint Blockade Therapy

• Published in: Small (Weinheim an der Bergstrasse, Germany) Vol. 17; no. 51; pp. e2105237 - n/a
• Main Authors: Wu, Han, Zhu, Jia‐Qi, Xu, Xin‐Fei, Xing, Hao, Wang, Ming‐Da, Liang, Lei, Li, Chao, Jia, Hang‐Dong, Shen, Feng, Huang, Dong‐Sheng, Yang, Tian
• Format: Journal Article
• Language: English
• Published: Germany Wiley Subscription Services, Inc 01.12.2021
• Subjects: Adjuvants; Antibodies; Antigens; biointerfacing nanoparticles; Carcinoma, Hepatocellular - drug therapy; checkpoint blockade; Domains; hepatocellular carcinoma; Humans; Immune system; Immunosuppression; Liver cancer; Liver Neoplasms - drug therapy; Lymphocytes; Macrophages; Nanoparticles; Nanotechnology; starvation therapy; Synergistic effect; T-Lymphocytes; Therapy; Tumor Microenvironment; tumor targeting; Tumors; checkpoint blockade; biointerfacing nanoparticles; tumor targeting; starvation therapy; hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the most fatal malignancies with few effective treatment options all around the world. The efficacy of the arisen immune checkpoint therapy is still uncertain due to local immunosuppression. In order to further overcome T cell suppression in the tumor immune...